Stockscreener 앱 받기
0.1755
2.50%
-0.0045
전일 마감가:
$0.18
열려 있는:
$0.189
하루 거래량:
117.77K
Relative Volume:
0.64
시가총액:
$7.19M
수익:
-
순이익/손실:
$-16.31M
주가수익비율:
-0.1835
EPS:
-0.9564
순현금흐름:
$-7.46M
1주 성능:
-5.08%
1개월 성능:
-13.08%
6개월 성능:
-45.46%
1년 성능:
-82.40%
1일 변동 폭
$0.175
$0.189
1주일 범위:
$0.175
$0.194
52주 변동 폭
$0.174
$1.38
Coeptis Therapeutics Holdings Inc Stock (COEP) Company Profile
명칭
Coeptis Therapeutics Holdings Inc
전화
724-934-6467
주소
105 BRADFORD ROAD, SUITE 420, WEXFORD
Coeptis Therapeutics Holdings Inc 주식(COEP)의 최신 뉴스
Exicure Shares More Than Double After Nasdaq Listing Extension - MarketWatch
Exicure Stock Is Soaring After The Bell: What's Driving The Action? - Benzinga
COHR’s Wild Ride: Up 82.75% – What’s Next for COHR? - The InvestChronicle
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.1% - Defense World
Choreo LLC Takes $333,000 Position in The Cooper Companies, Inc. (NASDAQ:COO) - Defense World
Quest Partners LLC Acquires New Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Exicure Inc (XCUR) rating downgrades by Chardan Capital Markets - Knox Daily
Cogent Biosciences Inc (COGT) stock analysis: A comprehensive overview - US Post News
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accep - GuruFocus.com
Choreo LLC Buys Shares of 6,902 Ziff Davis, Inc. (NASDAQ:ZD) - Defense World
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 4.1% - Defense World
Is Cogent Biosciences Inc (COGT) positioned for future growth? - SETE News
Quarterly Metrics: Quick and Current Ratios for Cogent Biosciences Inc (COGT) - The Dwinnex
Coherent Corp (COHR) receives a Buy rating from Needham - Knox Daily
Bank of New York Mellon Corp Buys 45,770 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Coeptis Therapeutics progresses in cell therapy trials - Investing.com
Coeptis Therapeutics progresses in cell therapy trials - Investing.com India
Coeptis Therapeutics progresses in cell therapy trials By Investing.com - Investing.com UK
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders - Nasdaq
Coeptis Therapeutics (NASDAQ:COEP) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS - Defense World
Coeptis Therapeutics to Present at the Emerging Growth Conferenc - GuruFocus.com
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Growth in Short Interest - Defense World
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - Longview News-Journal
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting - Longview News-Journal
Coeptis Therapeutics retracts financial statements due to errors - Investing.com
Daily Progress: Coeptis Therapeutics Holdings Inc (COEP) Drop -0.88, Closing at 0.20 - The Dwinnex
Holdings of Coeptis Therapeutics Holdings Inc (COEP) are aligned with the stars - SETE News
Riding the Waves: A Guide to Investing in COEP Stock - The InvestChronicle
Was anything negative for Coeptis Therapeutics Holdings Inc (COEP) stock last session? - US Post News
Market Insight: Coeptis Therapeutics Holdings Inc (COEP)’s Notable Drop, Closing at 0.24 - The Dwinnex
Critical Survey: Vir Biotechnology (NASDAQ:VIR) & Coeptis Therapeutics (NASDAQ:COEP) - Defense World
A Guide To The Risks Of Investing In Coeptis Therapeutics Holdings Inc (COEP) – Knox Daily - Knox Daily
LADENBURG THALM/SH SH Lowers Coeptis Therapeutics (NASDAQ:COEP) to Hold - Defense World
Coeptis Therapeutics Closes $4.3 Million Series A - citybiz
Coeptis Therapeutics Closes $4.3M Series A Funding - FinSMEs
Coeptis Therapeutics closes on $4.3 million Series APittsburgh Business Times - The Business Journals
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering - Quantisnow
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering - Quantisnow
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer - Quantisnow
Coeptis Therapeutics to Present at the Emerging Growth Conference - Quantisnow
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for ... - Quantisnow
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering - PR Newswire
COEP’s Stochastic Averages Dip: Analyzing Coeptis Therapeutics Holdings Inc’s Stock Performance - The InvestChronicle
Coeptis Therapeutics Holdings Inc (COEP) presents a great opportunity, but the stock is slightly overvalued – US Post ... - US Post News
Coeptis Therapeutics Holdings Inc's latest rating changes from various analysts – Knox Daily - Knox Daily
Head to Head Analysis: DBV Technologies (NASDAQ:DBVT) & Coeptis Therapeutics (NASDAQ:COEP) - Defense World
Is Coeptis Therapeutics Holdings Inc (COEP) positioned for future growth? – Sete News - SETE News
Coeptis Therapeutics Holdings Inc (COEP) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - Marketscreener.com
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - PR Newswire
Coeptis Therapeutics Holdings Inc (COEP) Clearly Signals Buy-Into the Stock: Don't ignore the signals – Sete News - SETE News
Coeptis Therapeutics Holdings Inc (COEP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
1.31%
자본화:
|
볼륨(24시간):